Ruxolitinib (S enantiomer)

Cat. No.: 0225LY-1359

Purity: ≥99%

Identity: Confirmed by NMR.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Ruxolitinib S enantiomer is the specific S-enantiomeric form of ruxolitinib, which is recognized as the inaugural potent and selective inhibitor of JAK1 and JAK2.

Synonym: S-Ruxolitinib; Ruxolitinib S enantiomer; INCB018424; 941685-37-6; S-Ruxolitinib; S-Ruxolitinib (INCB018424); Ruxolitinib (S enantiomer); (3s)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]propanenitrile; (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (betaS)-; (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (ent-Ruxolitinib); (S)-Ruxolitinib; (S)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; Ruxolitinib S enantiomer

CAS No.: 941685-37-6

Compound CID: 50878566

Formula: C₁₇H₁₈N₆

Formula Weight: 306.36

Specification

Targets&IC50: JAK2 (cell-free assay): 2.8 nM; JAK1 (cell-free assay): 3.3 nM; TYK2 (Cell-free assay): 19 nM

Relative Density: 1.40 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Ruxolitinib can be used in stereochemistry studies to evaluate the biological activity of the S-isomer compared to its pharmacological counterpart.